Cue Biopharma appointed James Ahlers as its new Chief Financial Officer, effective July 30, 2026. The executive employment agreement provides an annualized base salary of $450,000 and a discretionary bonus target of up to 45% of base salary. Upon appointment, Mr. Ahlers received an initial grant of nonstatutory stock options for 51,000 shares at an exercise price of $30.40 per share and restricted stock units for 25,500 shares, both vesting quarterly over four years. The agreement includes severance provisions equal to nine months of base salary plus target bonus in the event of a qualifying termination. Cue Biopharma operates in the biotechnology industry, focusing on drug discovery and development.
